» Articles » PMID: 29622568

Impact of Age and Comorbidity on Risk Stratification in Idiopathic Pulmonary Arterial Hypertension

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2018 Apr 7
PMID 29622568
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Recent reports from worldwide pulmonary hypertension registries show a new demographic picture for patients with idiopathic pulmonary arterial hypertension (IPAH), with an increasing prevalence among the elderly.We aimed to investigate the effects of age and comorbidity on risk stratification and outcome of patients with incident IPAH.The study population (n=264) was categorised into four age groups: 18-45, 46-64, 65-74 and ≥75 years. Individual risk profiles were determined according to a risk assessment instrument, based on the European Society of Cardiology and the European Respiratory Society guidelines. The change in risk group from baseline to follow-up (median 5 months) and survival were compared across age groups. In the two youngest age groups, a significant number of patients improved (18-45 years, Z= -4.613, p<0.001; 46-64 years, Z= -2.125, p=0.034), but no significant improvement was found in the older patient groups. 5-year survival was highest in patients aged 18-45 years (88%), while the survival rates were 63%, 56% and 36% for patients in the groups 46-64, 65-74 and ≥75 years, respectively (p<0.001). Ischaemic heart disease and kidney dysfunction independently predicted survival.These findings highlight the importance of age and specific comorbidities as prognostic markers of outcome in addition to established risk assessment algorithms.

Citing Articles

Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

Pentikainen M, Simonen P, Leskela P, Harju T, Jaaskelainen P, Asseburg C Pulm Circ. 2025; 15(1):e12440.

PMID: 39906120 PMC: 11791409. DOI: 10.1002/pul2.12440.


Explainable AI associates ECG aging effects with increased cardiovascular risk in a longitudinal population study.

Hempel P, Ribeiro A, Vollmer M, Bender T, Dorr M, Krefting D NPJ Digit Med. 2025; 8(1):25.

PMID: 39806125 PMC: 11730300. DOI: 10.1038/s41746-024-01428-7.


Performance of Risk-Stratification Scores for Patients With Pulmonary Arterial Hypertension in a Multi-Ethnic Asian Population.

Jiang H, Tan J, Ruan W, Hon J, Ismail A, Lim C Pulm Circ. 2024; 15(1):e70032.

PMID: 39737392 PMC: 11682694. DOI: 10.1002/pul2.70032.


Development and validation of a mortality predictive model for ICU patients with primary pulmonary hypertension.

Zhang C, Hu Y, Meng Z, Lu C, Xie Y, Yu Q Sci Rep. 2024; 14(1):31497.

PMID: 39732999 PMC: 11682143. DOI: 10.1038/s41598-024-83139-3.


Trends and levels of the global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021: findings from the global burden of disease study 2021.

Liu L, Li C, Cai J, Kong R, Wang Y, Wang Y Front Med (Lausanne). 2024; 11:1515961.

PMID: 39720660 PMC: 11666447. DOI: 10.3389/fmed.2024.1515961.